Epimedokoreanin B is a natural flavonoid with anticancer, anti-inflammatory and antibacterial effects. Epimedokoreanin B inhibits the growth of lung cancer cells through endoplasmic reticulum stress-mediated apoptosis accompanied by autophagosome accumulation. Epimedokoreanin B is an anti-periodontitis agent that inhibits gingipains and Porphyromonas gingivalis growth and biofilm formation . In Vitro Epimedokoreanin B (compound6; 3.13-25 μM; 48 hours) shows significate inhibitory effect on proliferation against lung cancer cell A549, Calu1 and H1299. Epimedokoreanin B displays no toxic on human bronchial epithelial cells BEAS-2B.\nEpimedokoreanin B treatment inhibits cell proliferation and migration accompanied by cytoplasmic vacuolation in A549 and NCI-H292 cells. Atophagosome accumulation accompanied with autophagy flux blocking is observed in Epimedokoreanin B treated cells, this was consistent with the occurrence of ER stress. Epimedokoreanin B (5 μM; 24 hours) inhibits CD163 expression and IL-10 production, which are known M2 markers, suggesting that Epimedokoreanin B inhibits M2 polarization in human monocyte-derived macrophages (HMDMs). Epimedokoreanin B suppresses STAT3 activation in HMDMs . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Cytotoxicity AssayCell Line: A549, Calu1 and H1299 cells Concentration: 3.13 μM, 6.25 μM, 12.5 μM and 25.0 μM Incubation Time: 48 hours Result: Showed significate inhibitory effect on proliferation against lung cancer cell A549, Calu1 and H1299. Western Blot Analysis Cell Line: Human monocyte-derived macrophages (HMDMs) Concentration: 5 μM Incubation Time: 24 hours Result: Significantly suppressed IL-10-induced JAK1/STAT3 activation.and H1299. In Vivo Epimedokoreanin B (20 mg/kg; p.o; thrice a week; for 17 days) inhibits tumor growth in an LM8 tumor-bearing murine model. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Female C3H mice (8-10 weeks old) injected with LM8 cellsDosage: 20 mg/kg Administration: Oral administration; thrice a week; for 17 days Result: Inhibited tumor growth. Form:Solid